Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China.
Faculty of Medicine, Macau university of science and technology, Macau University of Science and Technology, Taipa, Macau, China.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231171470. doi: 10.1177/15330338231171470.
Compared and analyzed the MRI imaging features of brain invasion otherwise benign (BIOB) meningiomas and WHO grade 1, grade 2 meningiomas, discussed the WHO grading of BIOB from the perspective of imaging.
A retrospective analysis was performed on 675 meningiomas patients who carried on MRI examination from January 2006 to February 2022. Setting the 2022 Central nervous system (CNS) WHO Guidelines as the gold standard for pathological diagnosis. Statistical analysis of age, gender, and MRI features of meningiomas in relation to WHO grade and brain invasion.
Among 675 cases meningiomas, 543 (80.4%) were WHO grade 1, 123 (18.2%) were WHO grade 2, and 9 (1.3%) were WHO grade 3. There were 108 cases meningiomas with brain invasion (BI) (16.0%) and 567 cases without BI (84.0%). Among BI cases, 67 cases were BIOB. Compared the MRI features between BIOB and WHO grade 1 meningiomas, multivariate analysis demonstrated that the most strongly factors associated with distinguish them were enhancement degree, peritumoral edema, tumor-brain interface, fingerlike protrusion, mushroom sign, and bone invasion (AUC: 0.925 (0.901∼0.945), sensitivity: 0.925, specificity: 0.801). Compared the MRI features between BIOB and WHO grade 2 meningiomas, multivariate analysis demonstrated that the most strongly factors associated with distinguish them were enhancement degree and the tumor-brain interface (AUC: 0.779 (0.686∼0.841), sensitivity: 0.746, specificity: 0.732), their efficacy was slightly weaker.
BIOB is more similar to WHO grade 2 meningiomas in clinical and imaging features than WHO grade 1, so we think that it may be reasonable to classify BIOB as WHO Grade 2 meningiomas in the guidelines.
比较并分析影像学表现有脑侵袭的 otherwise benign(BIOB)脑膜瘤和 WHO 1 级、2 级脑膜瘤的特点,从影像学角度探讨 BIOB 的 WHO 分级。
回顾性分析 2006 年 1 月至 2022 年 2 月间进行 MRI 检查的 675 例脑膜瘤患者。以 2022 年中枢神经系统(CNS)WHO 指南为病理诊断的金标准。统计分析脑膜瘤的年龄、性别和 MRI 特征与 WHO 分级和脑侵袭的关系。
在 675 例脑膜瘤中,543 例(80.4%)为 WHO 1 级,123 例(18.2%)为 WHO 2 级,9 例(1.3%)为 WHO 3 级。有 108 例脑膜瘤有脑侵袭(BI)(16.0%),567 例无 BI(84.0%)。在 BI 病例中,有 67 例为 BIOB。将 BIOB 与 WHO 1 级脑膜瘤的 MRI 特征进行比较,多因素分析表明,最能区分两者的因素是强化程度、瘤周水肿、肿瘤-脑界面、指状突起、蘑菇征和骨侵犯(AUC:0.925(0.901∼0.945),敏感性:0.925,特异性:0.801)。将 BIOB 与 WHO 2 级脑膜瘤的 MRI 特征进行比较,多因素分析表明,最能区分两者的因素是强化程度和肿瘤-脑界面(AUC:0.779(0.686∼0.841),敏感性:0.746,特异性:0.732),其效能稍弱。
BIOB 在临床和影像学特征上与 WHO 2 级脑膜瘤更为相似,而不是 WHO 1 级,因此我们认为在指南中将 BIOB 分类为 WHO 2 级脑膜瘤可能是合理的。